

## **AGENDA**

***Uniform Formulary Beneficiary Advisory Panel  
30 September 2015 @ 0900 AM***

***Naval Heritage Center Theater  
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 8:00 AM-9:00 AM)**
- **Sign In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

***Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.***

***The Committee made recommendations for the following drug classes during the May 2015 meeting:***

- ***Designated Newly Approved Drugs***
  - ***Long-Acting Muscarinic Antagonists (LAMAs)—Umeclidinium (Incruse)***
  - ***Targeted Immunomodulatory Biologics (TIBs)—Secukinumab injection (Cosentyx)***
- ***Drug Class Reviews:***
  - ***Non-Insulin Diabetes Drugs: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors***
  - ***Non-Insulin Diabetes Drugs: Glucagon-Like Peptide 1 (Receptor Agonists (GLP1RAs)***
  - ***Oral Oncology Drugs: Chronic Myelogenous Leukemia (CML)***
  - ***Narcotic Analgesics: Long Acting High Potency Narcotic Analgesics***
- ***Utilization Management Issues***
  - ***Prior Authorization Criteria***
    - ***Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors—Alirocumab (Praluent) and evolocumab (Repatha) injections***

- *Inhaled Corticosteroids—Fluticasone furoate (Arnuity Ellipta) and mometasone (Asmanex HFA) inhalers*
  - *Inhaled Corticosteroids/Long-Acting Beta Agonists Combinations—Fluticasone furoate/vilanterol (Breo Ellipta) inhaler*
  - *Pulmonary Fibrosis Drugs—Nintedanib (Ofev) and Pirfenidone (Esbriet)*
  - *Alzheimer’s Disease Drugs—Memantine extended release (Namenda XR) and memantine extended release/donepezil (Namzaric)*
  - *Sedative Hypnotics—Tasimelteon (Hetlioz)*
  - *Cystic Fibrosis Drugs—Lumacaftor/ivacaftor (Orkambi)*
  - *Topical Pain Products—Diclofenac Gel (Solaraze 3% Gel)*
  - *Compound Prescriptions*
- *National Defense Authorization Act Fiscal Year 2008, Section 703 Actions*
  - *Over-the-Counter (OTC) Drugs: UF Recommendations*
  - **Panel Discussions**

*The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.*